Login to Your Account

Pharma: Other News To Note

Monday, November 12, 2012
• Novo Nordisk A/S, of Bagsvaerd, Denmark, said the FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 8-4 in favor of approving insulin degludec and insulin degludec/insulin aspart with a post-approval cardiovascular outcomes trial commitment.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription